MDxHealth SA
Company Profile
Business description
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Contact
Zone Industrielle des Hauts-Sarts, Rue d’Abhooz, 31
Cap Business Center
Herstal
Liege4040
BELT: +32 43642070
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
312
Stocks News & Analysis
stocks
Has the most hated company on the ASX 200 bounced back?
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,922.00 | 4.90 | 0.05% |
| CAC 40 | 7,632.01 | 85.85 | 1.14% |
| DAX 40 | 23,757.69 | 331.72 | 1.42% |
| Dow JONES (US) | 44,134.01 | 545.43 | 1.25% |
| FTSE 100 | 9,128.30 | 59.72 | 0.66% |
| HKSE | 24,733.45 | 225.64 | 0.92% |
| NASDAQ | 21,027.54 | 377.41 | 1.83% |
| Nikkei 225 | 40,290.70 | 508.90 | -1.25% |
| NZX 50 Index | 12,684.04 | 45.36 | -0.36% |
| S&P 500 | 6,322.23 | 84.22 | 1.35% |
| S&P/ASX 200 | 8,663.70 | 1.70 | 0.02% |
| SSE Composite Index | 3,583.31 | 23.36 | 0.66% |